'Duodenal resurfacing' shows promise in T2DM
Half of the pilot study patients were still off insulin a year after the procedure: United European Gastroenterology (UEG) Week 2020
A single endoscopic duodenal mucosal resurfacing procedure, coupled with a GLP-1 receptor agonist and lifestyle coaching, might eliminate the need for insulin in most patients with type 2 diabetes, according to the results of a pilot study.
Duodenal mucosal hyperplasia occurs early in diabetes and contributes to insulin resistance.
Revita duodenal mucosal resurfacing, developed by Fractyl Laboratories, which funded the study, is a minimally invasive, outpatient endoscopic procedure that causes hydrothermal ablation, partially removing